<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01463878</url>
  </required_header>
  <id_info>
    <org_study_id>ANUS1014</org_study_id>
    <nct_id>NCT01463878</nct_id>
  </id_info>
  <brief_title>Enteral Nutrition and Glycemic Variability Neurological Intensive Care Unit Study</brief_title>
  <acronym>ANUS1014</acronym>
  <official_title>Enteral Nutrition and Glycemic Variability NICU Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Virginia Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Virginia Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To determine the effects of a diabetes specific enteral formula compared to a standard
      formula supplemented with protein (isocaloric and isonitrogenous) on the mean blood glucose
      and glycemic variability in a homogenous group of critically ill patients in a neurological
      ICU. Blood glucose will be recorded every minute using a continuous blood glucose monitor.
      The primary end points will be the difference between the mean blood glucose levels and the
      glucose variability between the control and intervention groups for the time period that the
      patient is in the ICU and receiving tube feeds and for up to a maximum of 14 days.

      Secondary Objectives:

      To determine the effects of the diabetes specific versus standard tube feeds on the change in
      muscle thickness and volume measured by 2-dimensional ultrasound imaging during the patients
      ICU stay.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unlikely to show statistical significance and slow recruitment.
  </why_stopped>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic Variability</measure>
    <time_frame>Entire ICU stay. Up to 14 days in the ICU (average about 7 days)</time_frame>
    <description>The patients blood glucose levels will be monitored with a continuous blood glucose monitor which records the calibrated blood glucose level every minute. The mean blood glucose over the patients entire ICU stay (up to 14 days) as well as the mathematical variation (fluctuation) in blood glucose levels will be calculated. The degree of glycemic variation will be assessed by a number of mathematical formula, including mean amplitude of glycemic excursions (MAGE). These parameters will be compared between the control and intervention groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quadriceps Muscle Volume</measure>
    <time_frame>First versus last measurment in ICU. Up to 14 days (average 7 days)</time_frame>
    <description>The quadriceps muscle volume will be estimated by 2-dimensional ultrasound imaging at enrollment and at the end of the study period (when the patient is being transferred from the ICU or no longer receiving tube feeds). The change in muscle mass during the ICU stay will be compared between the control and intervention groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <condition>Intracranial Hemorrhage</condition>
  <condition>Ischemic Strokes</condition>
  <condition>Subdural Hematoma</condition>
  <arm_group>
    <arm_group_label>Glycerna</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diabetic specific formula. The volume /rate of glycerna will be determined by the dietician according to standard formula.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - Jevity</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control arm of the study. Patients to receive Jevity. The volume /rate of Jevity will be determined by the dietician according to standard formula.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glycerna</intervention_name>
    <description>Diabetes specific formula</description>
    <arm_group_label>Glycerna</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Jevity - Control Diet</intervention_name>
    <description>Control Diet</description>
    <arm_group_label>Control - Jevity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged between 18 and 89 years old

          -  Patients with critical illness including ischemic or hemorrhagic stroke,
             epidural/subdural bleeds and subarachnoid hemorrhage

          -  Patients who are expected to stay in the ICU for at least 5 days

          -  Hyperglycemia is not an inclusion criteria

        Exclusion Criteria:

          -  Patients who have received or will be treated with systemic corticosteroids.

          -  Patients who will be receiving high doses of propofol (&gt;40 cc/hr)

          -  Patients with type 1 Diabetes

          -  Patients with sepsis or acute trauma

          -  Patients with an expected stay in the ICU of less than 4 days

          -  Patients who are unable to receive enteral nutrition or who have medical conditions
             precluding nutrition by the enteral route including allergies to formula components

          -  Pregnant and lactating patients

          -  Patients with prior history of gastroparesis

          -  Patients with acute kidney failure (creatinine &gt; 2.5mg/dl)

          -  Patients with acute liver failure (bilirubin &gt; 2.0 mg/dl)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul e Marik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>EVMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2011</study_first_submitted>
  <study_first_submitted_qc>November 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2011</study_first_posted>
  <results_first_submitted>June 22, 2012</results_first_submitted>
  <results_first_submitted_qc>August 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 28, 2012</results_first_posted>
  <last_update_submitted>October 3, 2012</last_update_submitted>
  <last_update_submitted_qc>October 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Virginia Medical School</investigator_affiliation>
    <investigator_full_name>Paul Marik</investigator_full_name>
    <investigator_title>Chief of Pulmnary and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>glycemic control</keyword>
  <keyword>glycemic variability</keyword>
  <keyword>mean blood glucose level</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hematoma</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Hematoma, Subdural</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>18 patients were consented and only 14 enrolled. 4 dropped out as failed to meet the inclusion criteria after consent; were bale to take food by mouth</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Glycerna</title>
          <description>Diabetic specific formula</description>
        </group>
        <group group_id="P2">
          <title>Control - Jevity</title>
          <description>The control arm of the study. Patients to receive Jevity</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>no longer met criteria for tube feed</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glycerna</title>
          <description>Diabetic specific formula</description>
        </group>
        <group group_id="B2">
          <title>Control - Jevity</title>
          <description>The control arm of the study. Patients to receive Jevity</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="12"/>
                    <measurement group_id="B2" value="74" spread="9"/>
                    <measurement group_id="B3" value="73" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glycemic Variability</title>
        <description>The patients blood glucose levels will be monitored with a continuous blood glucose monitor which records the calibrated blood glucose level every minute. The mean blood glucose over the patients entire ICU stay (up to 14 days) as well as the mathematical variation (fluctuation) in blood glucose levels will be calculated. The degree of glycemic variation will be assessed by a number of mathematical formula, including mean amplitude of glycemic excursions (MAGE). These parameters will be compared between the control and intervention groups.</description>
        <time_frame>Entire ICU stay. Up to 14 days in the ICU (average about 7 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycerna</title>
            <description>Diabetic specific formula</description>
          </group>
          <group group_id="O2">
            <title>Control - Jevity</title>
            <description>The control arm of the study. Patients to receive Jevity</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemic Variability</title>
          <description>The patients blood glucose levels will be monitored with a continuous blood glucose monitor which records the calibrated blood glucose level every minute. The mean blood glucose over the patients entire ICU stay (up to 14 days) as well as the mathematical variation (fluctuation) in blood glucose levels will be calculated. The degree of glycemic variation will be assessed by a number of mathematical formula, including mean amplitude of glycemic excursions (MAGE). These parameters will be compared between the control and intervention groups.</description>
          <units>mg/dl (MAGE)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" spread="40"/>
                    <measurement group_id="O2" value="166" spread="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quadriceps Muscle Volume</title>
        <description>The quadriceps muscle volume will be estimated by 2-dimensional ultrasound imaging at enrollment and at the end of the study period (when the patient is being transferred from the ICU or no longer receiving tube feeds). The change in muscle mass during the ICU stay will be compared between the control and intervention groups.</description>
        <time_frame>First versus last measurment in ICU. Up to 14 days (average 7 days)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Glycerna</title>
          <description>Diabetic specific formula</description>
        </group>
        <group group_id="E2">
          <title>Control - Jevity</title>
          <description>The control arm of the study. Patients to receive Jevity</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Paul Marik</name_or_title>
      <organization>Eastern Virginia Medical School</organization>
      <phone>757-446-8910</phone>
      <email>marikpe@evms.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

